Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Scynexis, Inc. develops innovative antifungal medicines, focusing on a proprietary platform of triterpenoid agents called fungerps. Its lead product, ibrexafungerp, is approved for vulvovaginal candidiasis and under development for systemic fungal infections. The company collaborates globally, leveraging licensing agreements and clinical trials to address resistant fungal pathogens, with a competitive edge in oral, broad-spectrum, fungicidal antifungals targeting unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.